VivoSeq
Gastroenterology

Necrotizing Enterocolitis

17

Pipeline Programs↗

4

Active Trials↗

10

Companies Involved↗

Necrotizing Enterocolitis is an emerging landscape with 17 programs across 10 companies. The most active players are Leadiant Biosciences, Inc., Roche, Neurim Pharmaceuticals Ltd.. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Leadiant Biosciences, Inc.

1 program

Phase 1Roche logo

Roche

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1GSK logo

GSK

1 program

Phase 1K

Kaken Pharmaceutical

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

7%ALL OTHERSProtein / enzyme17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 96% of 23 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed10 · 45%
Unknown status5 · 23%
Terminated3 · 14%
Not yet recruiting2 · 9%
Recruiting1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

22 trials

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis
Recruiting·NNoveome Biotherapeutics, formerly Stemnion·Phase 1/2·NCT06315738·36 enrolled
IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study
Active, not recruiting·IInfant Bacterial Therapeutics·Phase 3·NCT03978000·2,158 enrolled
Multi-strain Probiotics to Prevent Necrotizing Enterocolitis in Very Preterm Infants
Not yet recruiting·UUniversity of Calgary·Phase 3·NCT06810154·2,170 enrolled
Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC) - Clinical Study
Not yet recruiting·MMedical University of Warsaw·N/A·NCT06333405·20 enrolled
STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
Completed·LLeadiant Biosciences, Inc.·Phase 1·NCT01954017·103 enrolled
Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants
Completed·ZZekai Tahir Burak Women's Health Research and Education Hospital·Phase 3·NCT01531179·400 enrolled
Collaborative Research Group for Necrotizing Enterocolitis
Completed·WWashington University School of Medicine·N/A·NCT00828451·29 enrolled
Effect of Oral Probiotic Supplementation on The Rate of Hospital Acquired Infection and Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants
Completed·KKing Chulalongkorn Memorial Hospital·Phase 3·NCT01340469·160 enrolled
Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis
Completed·ZZhengzhou University·Phase 2·NCT03919500·1,285 enrolled
IBP-9414 for the Prevention of Necrotizing Enterocolitis
Completed·IInfant Bacterial Therapeutics·Phase 2·NCT02472769·120 enrolled
Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis
Completed·TTanta University·Phase 3·NCT06422000·75 enrolled
Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis
Completed·IIlocos Training and Regional Medical Center·Phase 1/2·NCT05033639·100 enrolled
Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants
Completed·—·Phase 4·NCT04304807·90 enrolled
Cohort of Premature Newborns for Charaterization of the Digestive Microbiota in Ulcerative Necrotizing Enterocolitis in Premature Infants
Completed·UUniversity Hospital, Clermont-Ferrand·Preclinical·NCT04972734·297 enrolled
CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis
Terminated·—·Phase 3·NCT03549507·1 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)